tradingkey.logo

Jupiter Neurosciences Inc

JUNS
查看詳細走勢圖
0.599USD
-0.016-2.65%
收盤 02/06, 16:00美東報價延遲15分鐘
20.56M總市值
虧損本益比TTM

Jupiter Neurosciences Inc

0.599
-0.016-2.65%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.65%

5天

+13.57%

1月

-43.18%

6月

-50.87%

今年開始到現在

-41.24%

1年

-41.24%

查看詳細走勢圖

TradingKey Jupiter Neurosciences Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Jupiter Neurosciences Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名131/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為25.00。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Jupiter Neurosciences Inc評分

相關信息

行業排名
131 / 392
全市場排名
269 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Jupiter Neurosciences Inc亮點

亮點風險
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
估值高估
公司最新PE估值-2.57,處於3年歷史高位
機構加倉
最新機構持股1.39M股,環比增加42.13%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉248.93K股

分析師目標

基於 1 分析師
買入
評級
25.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Jupiter Neurosciences Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Jupiter Neurosciences Inc簡介

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
公司代碼JUNS
公司Jupiter Neurosciences Inc
CEORosen (Christer)
網址https://jupiterneurosciences.com/
KeyAI